Taking effect in 2010, Pascal Soriot has been named chief operating officer of Roche‘s Pharma Division. Mr. Soriot previously served as chief executive officer of Genentech and is a member of the Corporate Executive Committee. He will have global responsibility for Pharma operations, including commercial operations worldwide, global marketing, production, development and registration. Ian Clark will succeed Mr. Soriot as chief executive officer of Genentech. He previously served as Head Global Product Strategy Pharma.

Jean-Jacques Garaud has been named to the Enlarged Executive Committee and has taken responsibility for Roche Pharma Research and Early Development. He is currently Head Pharma Development.

Daniel O’Day has been named chief operating officer of the Diagnostics Division and Member of the Executive Committee. He previously served as Head Roche Molecular Diagnostics.

Making room for the new appointees, William M. Burns (chief executive officer Pharma Division), Juergen Schwiezer (chief executive officer Diagnostics Division), and Jonathan Knowles (Head Group Research), will resign from the Corporate Executive Committee at the end of 2009. Mr. Schwiezer and Mr. Knowles will retire, while Mr. Burns, as announced previously, will be proposed as a member of the board.

Franz B. Humer, Chairman of the Roche Group, said: “William M. Burns, Jonathan Knowles and Juergen Schwiezer have significantly shaped Roche’s successful development over many years. All three have been instrumental in driving the Group’s overall success. We are deeply grateful for their tremendous contribution throughout their distinguished careers.”

Severin Schwan, chief executive offcier of the Roche Group, commented, “Following the conclusion of the Genentech integration we will continue to bring innovative healthcare solutions to patients worldwide through a diversity of research approaches and through efficient global development and commercialization. This broadened and younger Corporate Executive Committee will continue to drive Roche’s long-term vision as the world’s leading biotech company.”

Read our profiles of Roche and Genentech in our Top Companies Report!